Oncogenes and Tumor Suppressors
Under scientific review
Educational content. Use it to learn concepts, not for individual clinical decisions.
Genes participate in networks regulating division, survival and cellular maintenance. Some contribute to cancer when their activity increases; others when a protective function is lost. A gene name alone does not identify a variant’s effect.
Compare gain and loss of function; understand the two-hit hypothesis and its limits; separate a detected variant from a functionally relevant alteration.
Before you begin: What is cancer?, the cell cycle and DNA repair.
- Increased signaling
An oncogene can sustain an activity that was previously regulated.
- Reduced restraint
Loss of a suppressor can remove a barrier to growth.
- Biological context
Variant, dosage, tissue and other changes affect the outcome.
Accelerator and brake: a first approximation
A proto-oncogene has normal functions that can support growth or survival. Changes that increase or dysregulate its activity can make it an oncogene. A tumor suppressor limits processes that favor tumor formation or helps preserve cellular integrity.
“Accelerator” and “brake” help at first, but do not describe the whole network. Suppressors also participate in repair, differentiation and stress responses. Oncogenes do not arise only through a single DNA-letter change: expression, copy number and rearrangements also matter. American Cancer Society: genes and cancer.
| Mechanism | Example | Effect to investigate |
|---|---|---|
| Activating mutation | Some KRAS variants | Signaling activity less dependent on normal controls |
| Amplification | ERBB2, which encodes HER2 | Increased copy number may increase expression |
| Rearrangement | BCR::ABL1 fusion | A fusion protein with dysregulated kinase activity |
| Loss of function | RB1 or APC | Reduced control of the cycle or signaling |
| Epigenetic silencing | Promoter methylation in certain contexts | Lower expression without necessarily changing coding sequence |
Each row describes a possible mechanism, not every alteration in these genes. TP53 is the gene; p53 is the protein. This distinction prevents mixing a sequencing result with a protein-expression measurement.
Two hits and context
Knudson’s hypothesis helped explain retinoblastoma patterns: an inherited alteration can compromise one suppressor copy from the start; functional loss of the other can occur in a cell during life. In nonhereditary cases, both events can occur within the somatic lineage. Knudson, 1971.
- Identify the event: point variant, copy loss, amplification, rearrangement or regulatory change.
- Ask about function: did the protein lose activity, gain activity or change in abundance?
- Consider copies and tissue: effects depend on alleles, expression and other available pathways.
- Evaluate evidence: recurrence, experiments and tumor data contribute; no isolated filter resolves every case.
There is no obligatory count of “four to six drivers” that diagnoses cancer. Number and combination vary. It is also incorrect to say that every suppressor requires exactly two inactivated alleles.
Deeper dive: beyond the two-hit rule
In haploinsufficiency, one functional copy may not produce sufficient activity. In a dominant-negative effect, an altered protein interferes with the normal protein’s function; this has been investigated for p53 variants. Other variants may have additional effects. Thus, “one normal copy remains” does not end the analysis. Mechanistic p53 study.
Inheritance of a predisposition in a family and the effect of a change within a cell are different levels of explanation. An inherited predisposition is not an already-formed tumor.
From variant to meaning
Sequencing detects sequence changes; copy-number analysis investigates amplifications and losses; RNA measures expression; immunohistochemistry observes proteins in tissue. These are complementary observations, not perfect substitutes.
A pipeline usually detects, annotates and interprets variants. Annotation connects a position to a gene or transcript, but computational predictions do not prove that a variant is a driver. A variant of uncertain significance (VUS) remains uncertain even when the gene is well known. Tumor–normal comparison helps investigate somatic origin but requires quality and interpretation. NCI: BRCA testing and variants.
Biological mechanism alone also does not determine treatment. Blocking a hyperactive protein differs from restoring an absent function. Inhibiting CDK4/6 does not restore lost RB; strategies involving MDM2 must consider p53 functionality. Avoid “altered gene → drug” tables without variant, tumor, evidence and indication.
Guided example
Fictional scenario: a variant file contains a synonymous KRAS change and increased ERBB2 copies in another sample.
- A KRAS variant does not become activating merely because it lies in an oncogene; a synonymous change should not be classified automatically without context either.
- Increased copy number raises a different question: is the measurement reliable, and is expression increased?
- Separate technical detection, functional consequence and possible clinical significance. Each step requires its own evidence.
Check your understanding
Does every oncogene variant activate growth?
No. Consequences depend on the variant and context; the gene name is insufficient.
Does every suppressor require two hits?
No. It is an important model, but haploinsufficiency and dominant-negative effects show the rule’s limits.
Does computational annotation prove clinical relevance?
No. Annotation, function and clinical utility are distinct questions.